Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

264 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term efficacy and safety results of taliglucerase alfa up to 36 months in adult treatment-naïve patients with Gaucher disease.
Zimran A, Durán G, Mehta A, Giraldo P, Rosenbaum H, Giona F, Amato DJ, Petakov M, Muñoz ET, Solorio-Meza SE, Cooper PA, Varughese S, Chertkoff R, Brill-Almon E. Zimran A, et al. Among authors: varughese s. Am J Hematol. 2016 Jul;91(7):656-60. doi: 10.1002/ajh.24369. Epub 2016 Apr 24. Am J Hematol. 2016. PMID: 27174694 Free PMC article. Clinical Trial.
Long-term efficacy and safety results of taliglucerase alfa through 5years in adult treatment-naïve patients with Gaucher disease.
Zimran A, Durán G, Giraldo P, Rosenbaum H, Giona F, Petakov M, Terreros Muñoz E, Solorio-Meza SE, Cooper PA, Varughese S, Alon S, Chertkoff R. Zimran A, et al. Among authors: varughese s. Blood Cells Mol Dis. 2019 Sep;78:14-21. doi: 10.1016/j.bcmd.2016.07.002. Epub 2016 Jul 18. Blood Cells Mol Dis. 2019. PMID: 27499018 Free article.
Long-term safety and efficacy of taliglucerase alfa in pediatric Gaucher disease patients who were treatment-naïve or previously treated with imiglucerase.
Zimran A, Gonzalez-Rodriguez DE, Abrahamov A, Cooper PA, Varughese S, Giraldo P, Petakov M, Tan ES, Chertkoff R. Zimran A, et al. Among authors: varughese s. Blood Cells Mol Dis. 2018 Feb;68:163-172. doi: 10.1016/j.bcmd.2016.10.005. Epub 2016 Oct 20. Blood Cells Mol Dis. 2018. PMID: 27839981 Free article. Clinical Trial.
South African guidelines for the management of Gaucher disease, 2011.
Lysosomal Storage Disorder Medical Advisory Board; Bhengu L, Davidson A, du Toit P, Gerntholtz T, Govendragaloo K, Heitner R, Henderson B, Mubaiwa L, Varughese S. Lysosomal Storage Disorder Medical Advisory Board, et al. Among authors: varughese s. S Afr Med J. 2012 Jun 20;102(8):697-702. doi: 10.7196/samj.5439. S Afr Med J. 2012. PMID: 22831951
Diagnosis and management of Pompe disease.
Bhengu L, Davidson A, du Toit P, Els C, Gerntholtz T, Govendrageloo K, Henderson B, Mubaiwa L, Varughese S; Lysosomal Storage Disease Medical Advisory Board, South Africa. Bhengu L, et al. Among authors: varughese s. S Afr Med J. 2014 Apr;104(4):273-4. doi: 10.7196/samj.7386. S Afr Med J. 2014. PMID: 25118547 Review.
Effectiveness of the 13-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in South African children: a case-control study.
Cohen C, von Mollendorf C, de Gouveia L, Lengana S, Meiring S, Quan V, Nguweneza A, Moore DP, Reubenson G, Moshe M, Madhi SA, Eley B, Hallbauer U, Finlayson H, Varughese S, O'Brien KL, Zell ER, Klugman KP, Whitney CG, von Gottberg A; South African IPD Case-Control Study Group. Cohen C, et al. Among authors: varughese s. Lancet Glob Health. 2017 Mar;5(3):e359-e369. doi: 10.1016/S2214-109X(17)30043-8. Epub 2017 Jan 28. Lancet Glob Health. 2017. PMID: 28139443 Free article.
264 results